Display options
Cite
Sen S, Gürel N, Ufuktepe B, et al. Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI J. 2017;16:245-255doi: 10.17179/excli2016-725.
Sen, S., Gürel, N., Ufuktepe, B., Özünal, Z. G., Büyüklü, �. �., & Üresin, Y. (2017). Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI journal, 16245-255. https://doi.org/10.17179/excli2016-725
Sen, Selçuk, et al. "Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension." EXCLI journal vol. 16 (2017): 245-255. doi: https://doi.org/10.17179/excli2016-725
Sen S, Gürel N, Ufuktepe B, Özünal ZG, Büyüklü Ç, Üresin Y. Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension. EXCLI J. 2017 Mar 10;16:245-255. doi: 10.17179/excli2016-725. eCollection 2017. PMID: 28507470; PMCID: PMC5427471.
Copy Download .nbib Format: NLM
Share it on

EXCLI J. 2017 Mar 10;16:245-255. doi: 10.17179/excli2016-725. eCollection 2017.

Evaluating the relationship of blood pressure, plasma angiotensin peptides and aldosterone with cognitive functions in patients with hypertension.

EXCLI journal

Selçuk Sen, Nermin Gürel, Baran Ufuktepe, Zeynep Günes Özünal, Çagla Büyüklü, Yagiz Üresin

Affiliations

  1. Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, 34390 Fatih, Istanbul, Turkey.
  2. Department of Neuroscience, Institute of Experimental Medicine, Istanbul University, 34393 Fatih, Istanbul, Turkey.

PMID: 28507470 PMCID: PMC5427471 DOI: 10.17179/excli2016-725

Abstract

Renin Angiotensin Aldosterone System (RAAS) plays an important role in the development of hypertension. On the other hand, hypertension is a well-known and independent risk factor for cognitive impairment. The aim of the present study was to evaluate the relationship of blood pressure control, plasma angiotensin peptides and aldosterone with cognitive functions. Forty-one patients who were under treatment with the same antihypertensive medications for at least three months were included in the study. Plasma angiotensin II, angiotensin 1-7, angiotensin IV, and aldosterone concentrations were analyzed using an enzyme-linked immunosorbent assay (ELISA). Standardized Mini Mental State Examination (SMMSE) was used to evaluate cognitive functions. When the participants were grouped according to their SMMSE scores (cut-off value: 26 points), we determined significant differences between systolic blood pressure (SBP) levels, diastolic blood pressure levels, plasma angiotensin II and angiotensin 1-7 concentrations of the groups. When the participants were stratified according to their SBP levels (cut-off value: 140 mm Hg), we found significant differences in SMMSE scores and plasma angiotensin IV concentrations of the groups. A negative correlation between SBP and SMMSE scores and strong linear correlations among angiotensin peptides levels were determined. The relationship found between SBP and SMMSE in the present study was compatible with the literature. Our 33 patients were using at least one angiotensin II receptor blocker (ARB). Regarding AT1 receptor blockage, the significant association between higher SMMSE scores and increased angiotensin peptides may support a finding that ARBs prevent dementia and improve cognitive function. Further larger studies are needed to confirm and prove the relation of RAAS biochemical parameters with cognitive function.

Keywords: aldosterone; angiotensin; cognitive functions; hypertension

References

  1. Bratisl Lek Listy. 2005;106(1):3-19 - PubMed
  2. Circulation. 2005 Apr 12;111(14):1806-13 - PubMed
  3. J Alzheimers Dis. 2007 Mar;11(1):25-32 - PubMed
  4. Behav Brain Res. 2004 Sep 23;154(1):239-43 - PubMed
  5. Neuroscience. 2004;124(2):341-9 - PubMed
  6. J Pharmacol Exp Ther. 2009 Feb;328(2):478-86 - PubMed
  7. Br J Pharmacol. 1993 Sep;110(1):159-62 - PubMed
  8. Am J Hypertens. 2015 Mar;28(3):319-25 - PubMed
  9. J Hypertens. 2008 May;26(5):998-1007 - PubMed
  10. Cardiovasc Drugs Ther. 2013 Apr;27(2):133-8 - PubMed
  11. J Biol Chem. 2002 Jun 28;277(26):23107-10 - PubMed
  12. Neurol Res. 2004 Jul;26(5):502-6 - PubMed
  13. Turk Psikiyatri Derg. 2002 Winter;13(4):273-81 - PubMed
  14. J Cardiovasc Pharmacol. 1999 Aug;34(2):206-11 - PubMed
  15. Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2337-65 - PubMed
  16. BMC Neurosci. 2008 Dec 03;9 Suppl 2:S15 - PubMed
  17. Circ Res. 1991 Jun;68(6):1621-7 - PubMed
  18. Int J Biochem Cell Biol. 2003 Jun;35(6):792-801 - PubMed
  19. Handb Exp Pharmacol. 2006;(176 Pt 1):255-94 - PubMed
  20. Hypertension. 1995 Mar;25(3):305-13 - PubMed
  21. Physiol Behav. 2006 Jun 15;88(1-2):152-9 - PubMed
  22. Proc Natl Acad Sci U S A. 2007 May 22;104(21):9018-23 - PubMed
  23. Trends Cardiovasc Med. 2001 Nov;11(8):324-8 - PubMed
  24. BMC Geriatr. 2009 Nov 18;9:48 - PubMed
  25. Hypertension. 1995 Jun;25(6):1238-44 - PubMed
  26. Circ Res. 2004 Jun 11;94(11):1451-7 - PubMed
  27. Hypertens Res. 2011 Jan;34(1):74-8 - PubMed
  28. J Am Soc Hypertens. 2012 Sep-Oct;6(5):309-15 - PubMed
  29. Peptides. 2004 Jul;25(7):1195-203 - PubMed
  30. J Pharmacol Exp Ther. 1999 Dec;291(3):1242-9 - PubMed
  31. J Biol Chem. 1979 Jun 25;254(12):5120-7 - PubMed
  32. Vasc Health Risk Manag. 2007;3(1):125-37 - PubMed
  33. Cell Tissue Res. 2006 Nov;326(2):599-616 - PubMed

Publication Types